Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab for chronic inducible urticaria inadequately controlled with H1-antihistamines
2020-003018-11Phase 3Terminated
- Sponsor
- Novartis
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic inducible urticaria (CIndU), Cold urticaria (CU) and symptomatic dermatographism (SD) comparing Ligelizumab with Placebo (2 arms). Primary endpoints: Change from baseline in response to standardized provocation test and Symptomatic dermographism. Started Aug 2021; status: terminated.
02
Drugs
ligelizumab
03
Conditions
chronic inducible urticaria (CIndU)Cold urticaria (CU)symptomatic dermatographism (SD)
Beyond the preview
Go deeper on 2020-003018-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003018-11.